ArticleEClinicalMedicine2026
Association of antifungal treatment duration with 90-day mortality in critically ill adults with candidemia: a multicenter target trial emulation in France.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal duration of antifungal therapy for candidemia in intensive care unit (ICU) patients remains uncertain. We aimed to evaluate whether shorter antifungal therapy was not associated with increased mortality using a target trial emulation framework. Methods: We conducted a multicenter cohort study including adult ICU patients with candidemia from 16 ICUs in France (January 1, 2015 to January 1, 2023), emulating a target trial comparing short-course (<10 days) versus long-course (≥10 days) antifungal therapy. Patients treated for more than 21 days were excluded to minimize indication bias related to complicated candidemia. Patients who died within five days were excluded to ensure eligibility for both strategies. To account for time-dependent bias and confounding, we applied a cloning-censoring-weighting approach with inverse probability weighting. The primary outcome was all-cause mortality at day 90 after candidemia onset. Findings: Among 237 eligible patients with uncomplicated candidemia from the 492 enrolled in the CandidICU cohort, 48 (20.3%) received short-course and 189 (79.7%) long-course therapy. Overall 90-day mortality was 47.7% (113/237). Median age was 62 years [IQR 51-70], median SAPS II was 53 [40-68], and Interpretation: In this multicenter ICU cohort, among patients who survive the initial 5 days after candidemia onset and do not have obvious indication for prolonged therapy, short-course antifungal therapy was not associated with increased 90-day mortality after adjustment for time-dependent bias and confounders, although the confidence interval is wide and compatible with both clinically important benefit and harm. These findings are hypothesis-generating and should not alter current clinical practice. Randomized controlled trials are needed to definitively determine optimal treatment duration in critically ill patients. Funding: No funding was received for this work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.